The US Department of Veterans Affairs (VA) has the largest integrated health care delivery system in the nation and serves a large number of veterans living in rural locations. In an effort to improve patients' access to cardiology services, the VA began offering PCI programs at facilities without on-site CT surgery in 2005, coupled with strict quality oversight. Specifically, it established a national clinical quality oversight program-the Clinical Assessment, Reporting, and Tracking (CART) Program-for all VA cath labs that collected real-time data on cath laboratory Background-The safety of percutaneous coronary intervention (PCI) at medical facilities without on-site cardiothoracic (CT) surgery has been established in clinical trials. However, the comparative effectiveness of this strategy in real-world practice, including impact on patient access and outcomes, is uncertain. The Veterans Affairs (VA) health care system has used this strategy, with strict quality oversight, since 2005, and can provide insight into this question. Methods and Results-Among 24 387 patients receiving PCI at VA facilities between October 2007 and September 2010, 6616 (27.1%) patients underwent PCI at facilities (n=18) without on-site CT surgery. Patient drive time (as a proxy for access), procedural complications, 1-year mortality, myocardial infarction, and rates of subsequent revascularization procedures were compared by facility. Results were stratified by procedural indication (ST-segment-elevation myocardial infarction versus non-ST-segment-elevation myocardial infarction/unstable angina versus elective) and PCI volume.
I n randomized, controlled trials, provision of percutaneous coronary intervention (PCI) at medical facilities without on-site cardiothoracic (CT) surgery backup without compromising safety is possible. [1] [2] [3] [4] [5] Observational studies exploring the safety of PCI facilities without on-site CT surgery have generally supported these trial findings. [6] [7] [8] [9] [10] As a result, current PCI guidelines allow for the procedure at facilities without on-site CT surgery, but call for appropriate program development and quality oversight. 11 However, significant questions about this strategy remain unanswered, including its impact on patient access, longer-term outcomes, and the exact nature of effective quality oversight. procedures, complications, and outcomes. 12 The effectiveness of this policy on patient access to cath labs and their associated outcomes has not been systematically evaluated.
Accordingly, we conducted a comparative effectiveness study to evaluate median patient drive times to PCI facilities, as a proxy for patient access, as well as procedural and 1-year outcomes between patients undergoing PCI at medical facilities with and without on-site CT surgery services in VA cath labs between 2007 to 2010. We also assessed these end points as a function of procedural indication and cath laboratory volumes. It is hoped that these analyses will contribute to the current understanding of whether PCI programs can improve access to care without sacrificing quality of care in current clinical practice.
Methods

Data Sources
Access data for this analysis were collected from the VA Planning Systems Support Group, which provides geographic information system analysis for all VA facilities and beneficiaries. Using geocodes of patient home addresses and VA medical facilities, the group can determine distances and drive times between patients and their closest PCI facility, thus providing a standardized measure of access to the VA health care system. Preprocedural, procedural, and outcomes data for this analysis were collected from the VA CART Program. CART is a national clinicalquality program for all VA cath labs. 12 It uses a clinical software application, embedded in the VA electronic health record, to collect standardized patient and procedural data for all coronary procedures performed in VA cath labs nationwide. Data elements in the application are derived from the American College of Cardiology's National Cardiovascular Data Repository (NCDR) data definitions. 13 Quality checks of the CART data are periodically conducted for completeness and accuracy. Monthly, biannual, and annual reviews of CART data are conducted by the CART coordinating center, areas for improvement are targeted, and VA electronic medical record data are used to supplement CART patient data. The superiority of CART data validity, completeness, and timeliness has been previously demonstrated. 14 To capture longitudinal patient data, CART data are combined with other data from the VA patient electronic health record. These data include vital status, inpatient hospitalizations, outpatient clinic visits, pharmacy prescriptions and refills, and laboratory testing. In addition, the dataset is merged with VA fee-based data to account for those hospitalizations at non-VA facilities where the VA pays for the veterans' care.
Institutional review board and VA research and development approvals were obtained for the creation of the various datasets for our analysis.
Patient Population and Definitions
The analysis included all veterans receiving PCI in the VA between October 2007 and September 2010. For patients receiving multiple PCIs, we used their first PCI and the hospital where it was performed as the index PCI site.
The independent variable of interest was the presence of on-site CT surgery at the PCI facility. On-site CT surgery programs were determined by the VA Surgical Quality Improvement Program, which monitors all VA surgical programs and maintains updated lists of active programs. In addition, we verified this listing with the VA Office of Policy and Planning's Health Analysis Information Group 2011 national cardiovascular services survey.
Standard definitions for patient demographics and comorbidities were used. 13 PCI indications, anatomy, and complications were defined based on CART data elements. Major adverse events were defined as in-laboratory death, stroke, or need for emergent coronary artery bypass graft (CABG). Obstructive lesions were defined as any stenosis ≥70% in any epicardial artery or ≥50% in the left main coronary artery present at index PCI. The number of obstructive lesions attempted and successfully treated during the index PCI were both recorded. As per NCDR CathPCI data standards, successfully treated stenoses were defined as a residual stenosis ≤20% for PCI procedures, a residual ≤50% stenosis for balloon angioplasties without stenting, or a residual ≤50% stenosis and 20% difference in the pre-and posttreatment stenosis for chronic total obstructions. 15 Lesion risk was defined as high or nonhigh, as defined in the PCI guidelines. 11 Access was measured using the drive time between the veteran's primary residence, as recorded in their electronic health record, and the facility where they received their index PCI. Geocodes using the distance between patient home addresses and PCI facilities that integrate roadways and traffic patterns were used to calculate these times.
The primary procedural outcome was the occurrence of an in-laboratory need for emergent CABG (eg, to emergently repair a coronary artery dissection), as determined by the treating clinician. The primary 1-year outcome was combined all-cause mortality or hospitalization for nonfatal myocardial infarction (MI) following index PCI. Secondary outcomes included procedural in-laboratory death, 1-year mortality, 1-year MI, and 1-year unplanned revascularization (both PCI and CABG) rates. Mortality was measured using VA inpatient, VA encounter, VA fee-based, Centers for Medicare and Medicaid Services, and Social Security data files. MI was defined by ICD-9 codes of 410. xx in VA inpatient, VA fee-based, and CMS data files. We excluded MI codes occurring within the 14-day period after the index PCI, because previous studies and a targeted chart review (n=168) indicated that codes occurring before that time were related to the index presentation and PCI, rather than a de novo MI. 16 We also conducted a sensitivity analysis of all MI codes recorded after the index MI to ensure that this exclusion did not materially affect our primary findings. To account for those veterans who are dual covered with Medicare and VA benefits who may have been hospitalized in a non-VA hospital using their Medicare benefits, we conducted a secondary analysis that included all Medicare hospitalizations for MI in our cohort. To avoid counting staged PCI procedures, we removed those PCIs within the first 60 days of the index PCI if the procedure met all of the following criteria for being staged: it was not emergent, urgent, or salvage; the indication was not ST-segment-elevation myocardial infarction (STEMI) or non-STsegment-elevation myocardial infarction (NSTEMI); the patient was not in cardiogenic shock; and the PCI did not occur in the same vessel as the index PCI.
Statistical Analysis
Patient and procedural data (demographics, comorbidities, previous cardiac procedures, PCI indications, procedural results, and PCI complications) were collected and compared between groups. Categorical data were compared using χ 2 tests and continuous data using Mann-Whitney Wilcoxon nonparametric tests.
We sought to compare changes in patient access to VA PCI facilities that occur as a result of the provision of PCI at facilities without on-site CT surgery, using patient drive times as a proxy for access. First, we calculated median patient drive times using PCI facilities with and without on-site CT surgery (n=59). Next, we restricted our analysis to those PCI facilities with on-site CT surgery services (n=41) only, and recalculated median patient drive times between patient home and the closest VA PCI facility. Then, for those patients treated at facilities without on-site CT surgery, we calculated the difference in their drive time to the facility without on-site CT surgery and the closest facility with on-site CT surgery, then computed the median difference and interquartile range between drive times. We also conducted a subgroup analysis that compared access differences by PCI indication (STEMI versus NSTEMI/unstable angina [UA] versus elective). STEMI, NSTEMI, and UA were defined by the listed procedural indication in CART. Elective was defined by a listed procedural indication of stable angina, atypical chest pain, or other.
We calculated and compared both procedural and 1-year outcomes between patients receiving their index PCI at sites with and without on-site CT surgery services. Procedural in-laboratory need for emergent CABG was compared using χ 2 tests. One-year combined mortality and MI outcomes were calculated and compared between groups by guest on May 2, 2017 http://circ.ahajournals.org/ Downloaded from using log-rank tests and Kaplan-Meier curves. Cox regression modeling was used to adjust for covariates selected from the full model of the American College of Cardiology-NCDR PCI mortality risk prediction model. 17 For the 1-year MI models, we used covariates based on clinical reasoning and previous studies. [18] [19] [20] Covariates included age, sex, race, ethnicity, diabetes mellitus, dyslipidemia, hypertension, renal failure, cerebrovascular disease, peripheral arterial disease, body weight, chronic obstructive pulmonary disorder, smoking, and previous MI. A robust estimator of the covariance matrix was used to account for clustering by site. For individual revascularization outcomes, we identified any PCI or CABG recorded in the combined CART and VA dataset as specified above. We also conducted subgroup analyses of 1-year outcomes by PCI indication (STEMI versus NSTEMI/UA versus elective) and high versus low procedural volume. Volumes were dichotomized based on the median volume of VA cath labs (165 PCIs per year), with high volume defined as equal to or greater than the median value. We also conducted a sensitivity analysis categorizing facilities into procedural volume quartiles. For both subgroup analyses, interaction terms (site CT surgery status * PCI indication; site CT surgery status * PCI volume) were entered into our regression models to determine whether significant effect modification was present. For the PCI indication subgroup analysis, we also added median drive time between patient home and their PCI facility as a covariate to our regression models.
Results
PCI Patient and Procedural Characteristics
Between October 2007 and September 2010, 24 387 patients in 59 VA medical facilities underwent PCI. Six thousand, six hundred sixteen (27.1%) underwent PCI at 18 facilities without onsite CT surgery, and 17 771 (72.9%) patients underwent PCI at 41 facilities with on-site CT surgery (Table 1) . Compared with patients receiving PCI at facilities with on-site CT surgery, those at centers without on-site CT surgery had lower rates of previous MI (26.9% versus 32.4%, P<0.001), cardiac risk factors (eg, hypertension 90.8% versus 92.0%, P=0.002; diabetes mellitus 44.6% versus 46.2%, P=0.027), and noncardiac comorbidities (eg, depression 27.3% versus 28.9%, P=0.009; posttraumatic stress disorder 13.6% versus 15.7%, P<0.001).
In general, facilities without on-site CT surgery were more likely to perform PCI for elective, rather than STEMI or NSTEMI/UA, indications ( Table 2 ). In addition, they were more likely to perform PCI on high-risk (Type C) stenoses (41.6% versus 31.8%, P<0.001), and chronic total obstructions (4.5% versus 2.7%, P<0.001). They were also less likely to use drug-eluting stents (68.9% versus 70.7%, P=0.005). Figure 1 demonstrates the geographic distribution of PCI facilities with and without on-site CT surgery (n=59). The median drive time for patients to their respective PCI facility was 64.5 minutes (interquartile range [IQR], 26.0-133.3; Table 3 ). The median drive time for patients to the closest PCI facility with on-site CT surgery was 96.3 minutes (IQR, 37.4-166.9). The median patient-level difference in drive time for patients treated at facilities without on-site CT surgery and drive time to their closest facility with on-site CT surgery was 90.8 minutes (IQR, 20.2-112.5). This number represents only those patients treated at facilities without on-site CT surgery, so it is not the result of subtracting the median drive times for all patients to all facilities from the median drive times for all patients to their closest facility with on-site CT surgery.
Access
Among patients undergoing PCI for STEMI, the median drive time for patients treated at facilities with and without onsite CT surgery was 32.5 minutes (IQR, 16.5-82.1; Table 3 ). The median drive time for patients to the closest PCI facility with on-site CT surgery was 46.8 minutes (IQR, 19.4-124.1). The median patient-level difference in drive times between these 2 scenarios was 96.1 minutes (IQR, 30.0-113.6).
Among patients undergoing PCI for NSTEMI/UA, the median drive time for patients treated at facilities with and without on-site CT surgery was 59.3 minutes (IQR, 24.3-124.9; Table 3 ). The median drive time for patients to the Among those patients undergoing PCI for an elective indication, the median drive time for patients treated at facilities with and without on-site CT surgery was 76.6 minutes (IQR, 31.5-147.5; Table 3 ). The median drive time for patients to the closest PCI facility with on-site CT surgery was 107.7 minutes (IQR, 45.7-175.0). The median patient-level difference in drive times between these 2 scenarios was 87.2 minutes (IQR, 15.00-110.9).
Outcomes
During October 2007 and September 2010, 15 (0.1%) PCI complications requiring emergent CABG surgery occurred ( Table 2 ). Rates of these complications between PCI facilities without and with on-site CT surgery were similar (n=2 [<0.05%] emergent CABG at PCI facilities without on-site CT surgery versus n=13 [0.1%] at PCI facilities with on-site CT surgery, P=0.382). Procedural in-laboratory death rates were similar (n=4 [0.1%] deaths at PCI facilities without onsite CT surgery versus n=16 [0.1%] at PCI facilities with onsite CT surgery, P=0.618).
Unadjusted 1-year combined mortality and MI rates were also similar between PCI facilities without and with on-site CT surgery (8.4% versus 8.7%, log-rank P=0.51; Figure 2 ). After multivariable adjustment, outcomes remained similar by facility (hazard ratio [HR] for patients at sites without on-site CT surgery versus those patients at sites with on-site CT surgery, 1.02; 95% confidence interval [CI], 0.87-1.2; Figure 3 ). Individual 1-year mortality (6.0% at sites without on-site CT surgery; 6.5% at sites with on-site CT surgery; adjusted HR, 0.99; 95% CI, 0.8-1.22), and MI (2.9% at sites without on-site CT surgery; 2.6% at sites with on-site CT surgery; adjusted HR, 1.14; 95% CI, 0.93-1.38) outcomes were also similar by facility. Secondary analyses incorporating MI hospitalizations in non-VA hospitals among Medicare beneficiaries did not significantly affect the primary results. One-year subsequent, unplanned revascularization rates were higher in patients treated at PCI facilities without on-site CT surgery (15.2% at sites without on-site CT surgery; 12.7% at sites with on-site CT surgery; adjusted HR, 1.21; 95% CI, 1.03-1.42), because of higher subsequent PCI rates (13.8% at sites without on-site CT surgery; 11.0% at sites with on-site CT surgery; adjusted HR, 1.28; 95% CI, 1.07-1.52). Inclusion of the MI codes occurring within the 14-day period after the index MI did not materially affect our primary findings.
Among patients undergoing PCI for STEMI, 1-year combined outcomes (15.7% at sites without on-site CT surgery; 13.8% at sites with on-site CT surgery; adjusted HR, 1.34; 95% CI, 0.91-1.98), mortality rates (12.9% at sites without on-site CT surgery; 12.4% at sites with on-site CT surgery; adjusted HR, 1.25; 95% CI, 0.82-1.89), and MI rates (15.7% at sites without on-site CT surgery; 13.8% at sites with on-site CT surgery; adjusted HR, 1.67; 95% CI, 0.97-2.89) were similar (Figure 4 ). Among patients undergoing PCI for NSTEMI/UA, 1-year combined outcomes (10.1% at sites without on-site CT surgery; 10.5% at sites with on-site CT surgery; adjusted HR, 0.99; 95% CI, 0.81-1.21), mortality rates (7.0% at sites without on-site CT surgery; 7.3% at sites with on-site CT surgery; adjusted HR, 0.99; 95% CI, 0.77-1.29), and MI rates (3.9% at sites without on-site CT surgery; 3.6% at sites with on-site CT surgery; adjusted HR, 1.09; 95% CI, 0.85-1.4) were also similar. Finally, among patients undergoing PCI for an elective indication, 1-year combined outcomes (5.2% at sites without on-site CT surgery; 5.0% at sites with on-site CT surgery; adjusted HR, 0.99; 95% CI, 0.81-1.22), mortality rates (3.7% at sites without on-site CT surgery; 3.6% at sites with on-site CT surgery; adjusted HR, 0.98; 95% CI, 0.76-1.26), and MI rates (1.6% at sites without on-site CT surgery; 1.5% at sites with on-site CT surgery; adjusted HR, 1.09; 95% CI, 0.79-1.49) were similar. The interaction term for the 1-year combined outcome by the presence of on-site CT surgery stratified by PCI indication was not significant. Inclusion of median drive time in our models did not affect the results.
The median volume of PCIs among all VA cath labs was 165 PCIs per year (IQR, 124-234). Among PCI facilities without on-site CT surgery, the median PCI volume was 126 per year (IQR, 87-180) and among facilities with onsite CT surgery, the median PCI volume was 180 per year (IQR, 132-255). Among patients undergoing PCI at lower volume facilities, there were no differences in 1-year combined outcomes (8.2% at sites without on-site CT surgery; 8.7% at sites with on-site CT surgery; adjusted HR, 1.04; 95% CI, 0.83-13), mortality rates (5.5% at sites without on-site CT surgery; 5.6% at sites with on-site CT surgery; adjusted HR, 0.95; 95% CI, 0.75-1.19), and MI rates (3.2% at sites without on-site CT surgery; 2.5% at sites with onsite CT surgery; adjusted HR, 1.21; 95% CI, 0.89-1.66) ( Figure 5 ). Among patients undergoing PCI at higher volume facilities, there were also no differences in 1-year combined outcomes (8.6% at sites without on-site CT surgery; 9.2% at sites with on-site CT surgery; adjusted HR, 1.03; 95% CI, 0.85-1.25), mortality rates (6.3% at sites without on-site CT surgery; 6.8% at sites with on-site CT surgery; adjusted HR, 1.03; 95% CI, 0.8-1.31), and MI rates (2.7% at sites without on-site CT surgery; 2.7% at sites with on-site CT surgery; adjusted HR for 1-year MI, 1.05; 95% CI, 0.83-1.32). The interaction term for the 1-year combined outcome by the presence of on-site CT surgery stratified by cath laboratory volume was nonsignificant. The sensitivity analysis categorizing facilities by procedural volume quartile did not materially affect our primary findings.
Discussion
This comparative effectiveness study evaluated PCI access and outcomes between facilities with and without on-site CT surgery in a national integrated health care system. We found that providing PCI facilities without on-site CT surgery resulted in significantly shorter drive times for patients to PCI facilities. At the same time, rates of procedural complications and 1-year mortality and MI between patients treated at facilities with and without on-site CT surgery were not significantly different. These findings were consistent for PCIs performed regardless of procedural indication or facility PCI volume. Taken together, these results suggest that allowing PCI at facilities without on-site CT surgery improves patients' access to the procedure without comprising their outcomes.
Two randomized, controlled studies, the Atlantic Cardiovascular Patient Outcomes Research Team and Atlantic Cardiovascular Patient Outcomes Research Team E trials, demonstrated that PCI performed either for primary STEMI or elective indications at facilities without on-site CT surgery was safe. 3, 21 Observational studies exploring the safety of PCI facilities without on-site CT surgery have generally supported these trial findings. [6] [7] [8] [9] [10] Current PCI guidelines assign a Class IIa (is reasonable) recommendation for primary PCI and Class IIb (might be considered) recommendation for elective PCI at facilities without on-site CT surgery services with appropriate program development and quality oversight. 11 However, concerns have persisted that variable patient case-mix and PCI volume may contribute to worse real-world outcomes among off-site CT surgery facilities. Furthermore, the impact of these facilities on patient access is unknown. Finally, the nature of effective quality oversight for these programs is ill defined. Our study provides unique insights into each of these open questions.
In the VA, provision of PCI facilities without on-site CT surgery appeared to improve patient access to PCI without comprising their safety. The median decrease in patient drive time with the inclusion of the 18 PCI facilities without onsite CT surgery was approximately an hour and a half-a substantial improvement, especially for those experiencing an acute coronary syndrome. At the same time, both periprocedural and 1-year outcomes were similar between facilities. Together, these findings suggest that proper patient selection, as well as effective procedural technique, were consistently used. Similar outcomes were seen whether PCI was performed for either STEMI, NSTEMI/UA, or elective indications, supporting the current Class II recommendations for its use. 11 We also demonstrated that similar outcomes occurred even in lower volume PCI facilities. This is especially important in the VA, because the median PCI volume in VA cath labs is low-only 165 PCIs per year. 11 We did note higher rates of unplanned PCI among facilities without on-site CT surgery in the year after the index PCI. The reasons behind this finding are unclear, but may represent a lower initial PCI success rate or a more conservative approach by interventionalists at these facilities. Regardless of the reasons, this difference in revascularization rates was not accompanied by a safety signal of harm at 1 year.
In 2005, the VA instituted a policy to allow for both primary and elective PCI at facilities without on-site CT surgery to improve PCI access for its veteran population. PCI facilities and providers undergo rigorous certification processes before beginning PCI procedures, including verification of board certification in interventional cardiology for all provides and formal site review of each catheterization laboratory to ensure best practices for PCI patient selection, technical performance, and staffing. The national VA CART Program also provides formal quality oversight for all 59 PCI facilities in the VA. CART systemically collects real-time, standardized patient and procedural data on all coronary procedures performed. Through this process, the CART program can detect major adverse events, such as PCI complications requiring emergent CABG surgery or in-laboratory deaths. An independent national peer committee of VA interventional cardiologists reviews each major adverse event, and any quality issues are identified and corrected in conjunction with the affected laboratory. In addition, quality improvement insights are shared with the national cath laboratory community to allow for continual examination and improvement of cath laboratory safety. Accordingly, the CART program fulfills the 2011 PCI guideline recommendations for "appropriate planning for program development," "proper patient selection," and "on-site rigorous data collection, outcomes analysis, benchmarking, quality improvement, and formalized periodic case review" for PCI facilities without on-site CT surgery and serves as a potential model for other health care systems. 11 This study has several potential limitations. First, the study cohort is observational, and thus there may be residual confounding. Although we observed similar risk-adjusted outcomes, we cannot be certain there were not additional variables that differ between centers with and without CT surgery related to the outcomes. However, the observation of similar unadjusted and adjusted mortality rates, and overall low adverse event rates at both types of facilities, suggests that overall outcomes are truly similar. Second, the index PCI procedure being done at sites with or without on-site CT surgery services is only 1 factor of many that may affect 1-year mortality and MI outcomes in this population. However, the intent of our analysis was to demonstrate the longer-term safety of the strategy in conducting PCI between these 2 sites, rather than accounting for all post-PCI variables that could have potentially influenced the outcomes. Moreover, we observed low and similar periprocedural major adverse events at both types of facilities. Third, many VA interventionalists practice at both VA and non-VA facilities, so their procedural volume may be substantially higher than the VA laboratory volume and have important effects on periprocedural outcomes. Unfortunately, October 14, 2014 we do not have total operator volume to incorporate into our models. Fourth, as with any study conducted in the VHA, the predominantly male population may limit the generalizability of our findings to female populations. However, we have no a priori reason to think that there would be gender differences for this study question. Fifth, it is possible that our outcomes of interest in patients with private or unknown health insurance would not have been captured in either VA or CMS data. However, the rates of this insurance is relatively low and similar between groups (16.2% at sites with and 14% at sites without on-site CT surgery), and the rates of on-going care at the VA for all patients, regardless of insurance type, exceed 95%. Thus, the potential for significant underreporting of outcomes is small. Finally, the integrated nature of the VA health care system, the unique aspects of the national VA quality oversight program, and low PCI volumes in the VA may reduce the generalizability of our findings to non-VA settings without these characteristics. However, the quality oversight features inherent in the VA CART program can be replicated in non-VA settings, and the national move toward greater health care integration and accountable care organizations may necessitate emulating the VA's approach.
Conclusions
In conclusion, this comparative effectiveness study suggests that providing PCI at facilities without on-site CT surgery can improve patient access without comprising patient safety. These results suggest that clinical trial evidence and current guideline recommendations that support PCI without on-site CT surgery can be effectively translated into clinical practice. In addition, these results provide a potential model for PCI quality oversight for health care systems using such an approach to PCI services.
